Brookline Capital Management Predicts YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a note issued to investors on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.75) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.66) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($0.94) EPS.

Several other research firms have also weighed in on YMAB. Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. BMO Capital Markets decreased their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Trading Up 2.3 %

Shares of YMAB stock opened at $10.54 on Monday. Y-mAbs Therapeutics has a twelve month low of $6.09 and a twelve month high of $20.90. The stock has a market cap of $472.09 million, a price-to-earnings ratio of -19.52 and a beta of 0.61. The company’s 50-day moving average price is $13.24 and its 200-day moving average price is $12.76.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the business posted ($0.18) EPS.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics in the third quarter valued at $44,000. China Universal Asset Management Co. Ltd. raised its position in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth $133,000. SG Americas Securities LLC purchased a new position in Y-mAbs Therapeutics during the 3rd quarter worth $178,000. Finally, Empire Financial Management Company LLC acquired a new position in Y-mAbs Therapeutics in the third quarter valued at $210,000. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at $1,315,763.07. The trade was a 39.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.50% of the stock is currently owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.